Metabolic disturbances of second generation antipsychotics in stable long term outpatients: a two years follow up study

2016 ◽  
Author(s):  
Diego Mendez
Keyword(s):  
Second Generation ◽  
Metabolic Disturbances ◽  
Follow Up Study ◽  
Second Generation Antipsychotics

Predictors of response to second generation antipsychotics in drug naïve patients with schizophrenia: A 1 year follow-up study in Shanghai

2014 ◽  
Vol 215 (1) ◽  
pp. 20-25 ◽  
Author(s):  
Hong-Xia Zhang ◽  
Xiao-Ling Shen ◽  
Hui Zhou ◽  
Xiao-Min Yang ◽  
Hui-Fang Wang ◽  
...  
Keyword(s):  
Second Generation ◽  
Follow Up Study ◽  
Predictors Of Response ◽  
Second Generation Antipsychotics ◽  
Drug Naïve

scholarly journals Current and Novel Approaches to Mitigate Cardiometabolic Adverse Effects of Second-Generation Antipsychotics

2020 ◽  
Vol 23 (8) ◽  
pp. 491-495
Author(s):  
Karolina Skonieczna-Żydecka ◽  
Igor Łoniewski ◽  
Ewa Stachowska ◽  
Wojciech Marlicz ◽  
Christoph U Correll
Keyword(s):  
Adverse Effects ◽  
Second Generation ◽  
Public Health Issue ◽  
Cardiometabolic Health ◽  
Metabolic Disturbances ◽  
Major Public Health Issue ◽  
Second Generation Antipsychotics ◽  
Second Generation Antipsychotic ◽  
Pharmacologic Treatments

Abstract Second-generation antipsychotic–related weight gain and metabolic disturbances are a major public health issue given the widespread prescribing of these medications. The lack of clearly known mechanisms of cardiometabolic adverse effects and the relevance of cardiometabolic health for survival make this an important area for research. While nonpharmacologic and some pharmacologic treatments have shown benefits vs control conditions or placebo, the effects are modest and long-term benefits are less clear. Therefore, new approaches to mitigate second-generation antipsychotic–associated cardiometabolic burden are sorely needed.

Sign in / Sign up

Export Citation Format

Share Document